Founder, Ligant.ai
Founder, Ligant.ai  ·  Pharma 5.0

The Operating System for
Pharma 5.0

I'm A.B. Modi, founder of Ligant.ai. We are building the human and machine collaboration layer for cell and gene therapy biotech. One platform where R&D, regulatory, and quality teams move at the speed, accuracy, and confidence that modern drug discovery demands.

Explore Ligant.ai → Read the Vision
A.B. Modi, Founder of Ligant.ai
A.B. Modi
Founder, Ligant.ai

Why Drug Discovery Is Slower Than It Should Be

The science is ready. The regulations exist for good reason. What is missing is the connective tissue: a place where every stakeholder inside a biotech can collaborate on the same evidence, with the same rigor, and at the same machine assisted speed. That is the gap Ligant.ai is built to close.

Pharma 5.0 · Human and Machine Collaboration

Pharma 4.0 digitized the lab. Pharma 5.0 changes who does the work.

Cell and gene therapy is advancing faster than the tools supporting it. Founders and scientists still stitch together evidence across 20+ databases, write submissions from scratch, and lose months to work that machines can do honestly, with citations and audit trails, in a fraction of the time.

Ligant.ai keeps the scientist as the decision-maker and gives them an agentic team that handles the data-intensive synthesis. Every claim is cited. Every decision is logged. Nothing is hidden behind a black box.

  • Scientists decide. Agents do the evidence work.
  • Claim-level citations, append-only audit trails.
  • One system for R&D, regulatory, and quality work.
Weeks → Days

From hypothesis to investor grade target dossier, without sacrificing rigor.

20+ biomedical sources · cited at the claim

What Ligant.ai Is Building

We are starting where the pain is sharpest for cell and gene therapy founders, then expanding into the full operating layer biotech teams need to run with confidence.

Live Today

R&D: CAR-T Target Assessment

An agentic head of target assessment for pre seed and pre Series A founders. Consulting grade CAR-T evaluation across biological, strategic, and economic viability, delivered in weeks rather than months.

  • ✓ Three-Gate Framework
  • ✓ 20+ Database Synthesis
  • ✓ Claim-Level Citations
On the Roadmap

Regulatory Affairs

Agentic workflows that track global regulatory changes, draft IND and NDA technical writing, and assemble submission ready dossiers, with every section traceable to source.

  • ✓ Global Reg-Change Tracking
  • ✓ Submission Doc Automation
  • ✓ Source-Traceable Sections
On the Roadmap

Quality Operations

QMS orchestration built for cell and gene therapy realities: deviation management, CAPA cycles, and continuous audit readiness, wired into the same evidence layer your R&D team uses.

  • ✓ QMS Orchestration
  • ✓ Deviation & CAPA Automation
  • ✓ Continuous Audit Readiness
Visit Ligant.ai →

Why I'm Building This

Over fifteen years building businesses, building software, and shipping product for hundreds of companies. Five years embedded inside pharma and biotech. The gap kept showing up in the same places, so I decided to build the platform that closes it.

Operator Foundation

15+ Years Building Software, Building Businesses

From bootstrapped startups to enterprise workflows, I have architected and shipped software for hundreds of companies, translating messy business problems into systems that operators actually use.

100s
Companies Served
15+ yrs
Operator + Builder
Operator and software builder
Pharma and biotech work
Domain Immersion

5 Years Inside Pharma & Biotech

Embedded with QA, RA, and HEOR teams across pharma and biotech for over five years, with a deep focus on cell and gene therapy companies. The pattern repeats across every program: rigorous science, full respect for the regs, and no shared system that lets cross functional teams move at the speed and accuracy the industry now demands.

QA · RA · HEOR
Functions Embedded With
CGT
Cell & Gene Therapy Focus
The Thesis

Computational Power Is the New Bench

The compute is here. The models are here. What is missing is a faithful, auditable, scientist led system that puts all of it to work on the hardest parts of drug discovery, starting with cell and gene therapy, where the science is moving fastest.

Human-Led
AI-Powered
Audit-Ready
By Default
Computational drug discovery

How Ligant.ai Works

A scientist-led loop where agents do the synthesis, humans make the calls, and every decision leaves a trail.

01

Frame the Question

Scientists define the target, hypothesis, or decision they need to make. The platform translates intent into an evidence plan.

02

Agentic Synthesis

Specialist agents query 20+ biomedical databases, reconcile sources, and assemble evidence with every claim cited at the line level.

03

Human Decision Gates

Critique agents stress-test the conclusions. Scientists review, push back, and make the call. The platform halts when evidence is insufficient.

04

Audit-Ready Output

Dossiers, target assessments, and submission grade artifacts, each backed by an append only audit trail behind every word.

Let's Build Pharma 5.0 Together

If you are a cell or gene therapy founder, scientist, or operator, or you want to work with us on Ligant.ai, I would love to hear from you.

Go to Ligant.ai →